Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q3 EPS of ($0.06), $0.05 worse than the analyst estimate of ($0.01). Revenue for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE